Methylphenidate for Cocaine Dependence

Summary

This phase II pilot study aims at evaluating the benefits and the risks of methylphenidate (Concerta®) for the treatment of cocaine/crack dependence in terms of cocaine/crack use reduction and adverse events.

Timeline

Start

2018-06-01

Primary completion

2018-12-31

Completion

2019-03-30

Outcome

Outcome not reported

Stopped: “feasibility reasons.”

Drugs

Indications